AstraZeneca drug Fasenra fails to achieve main goal in COPD trial [Reuters]
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Reuters
AstraZeneca drug Fasenra fails to achieve main goal in COPD trial | Reuters Reuters Staff 1 Min Read (Reuters) - AstraZeneca’s first respiratory biological medicine Fasenra failed to meet its main target in a second clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD). The drug is currently approved as an add-on treatment for severe eosinophilic asthma in the United States, the European Union, Japan and several other countries. Fasenra failed to meet its target in the final-stage trial, named Galathea, this month. Reporting By Justin George Varghese in Bengaluru; Editing by David Goodman All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. Š 2018 Reuters. All Rights Reserved.
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- Insights Into Astrazeneca (AZN) Q1: Wall Street Projections for Key Metrics [Yahoo! Finance]Yahoo! Finance
- With 85% ownership, AstraZeneca PLC (LON:AZN) boasts of strong institutional backing [Yahoo! Finance]Yahoo! Finance
- Vaccines Market worth $65.3 billion by 2028: BCC Research LLC [Yahoo! Finance]Yahoo! Finance
- You may have inherited risks of developing cancer: Here's what you need to know [CBS News]CBS News
- Sermonix to Host KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape on April 22, 2024 [Yahoo! Finance]Yahoo! Finance
AZN
Sec Filings
- 4/11/24 - Form 6-K
- 4/11/24 - Form 6-K
- 4/8/24 - Form 6-K
- AZN's page on the SEC website